ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture

Michele B. Kaufman, PharmD, BCGP  |  February 15, 2023

In late December, the FDA approved subcutaneous abaloparatide for the treatment of men with osteoporosis at a high risk of fracture. This approval is based on a placebo-controlled study that showed abaloparatide led to significant increases in bone mineral density of the lumbar spine, total hip and femoral neck. Abaloparatide was approved in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Healthcare Policy Prospects in the 118th Congress

From the College  |  February 4, 2023

The U.S. government remains divided. Democrats hold the White House and the Senate by one vote, and Republicans lead the House. Amid this division, the ACR is watching possible areas to advance healthcare legislation. Meet the committees and members with the largest jurisdiction over healthcare policy.

Reform of Medicare Payment System Needed to Maintain Patient Care, ACR Says

From the College  |  February 2, 2023

In a joint letter, the ACR urges Congress to undergo comprehensive reform of the Medicare payment system and seek long-term payment solutions that will allow clinicians to continue to care for Medicare patients.

How Long Should Methotrexate Be Held Following Seasonal Vaccinations?

Arthritis & Rheumatology  |  February 1, 2023

Vaccinations against preventable diseases, including seasonal influenza, are strongly recommended for patients with rheumatoid arthritis (RA), who are at increased risk of infections as a result of underlying immune dysfunction and treatment-induced immunosuppression. Park et al. conducted this clinical trial to investigate whether discontinuing methotrexate for one week after seasonal influenza vaccination is noninferior to discontinuing it for two weeks after vaccination in patients with RA.

Rheumatology Online: Disseminating the State of the Art on Social Media at ACR Convergence 2022

Mithu Maheswaranathan  |  January 30, 2023

PHILADELPHIA—A session on social media in rheumatology at ACR Convergence 2022 focused on how to use social media to promote one’s work and collaborate on international research projects, as well as the use of podcasts in educating rheumatologists. Engaging with Social Media at Conferences Jean Liew, MD, MS, assistant professor of medicine in the Section…

Key Facts on Billing Drug Wastage

From the College  |  January 24, 2023

The ACR has compiled guidelines and tips on how to use the JW modifier and correctly bill Medicare for discarded drugs and biologicals. This modifier can be applied only to unused amounts from a single-dose vial or package.

CMS Announces Timeline for Drug Negotiations

From the College  |  January 20, 2023

This month, the CMS will begin steps to develop a drug pricing negotiation process as allowed by the Inflation Reduction Act. The ACR plans to participate in public comment opportunities.

The ACR Announces New Community Practice Council; Applications Now Open

From the College  |  January 10, 2023

The new council, comprising professionals from small or independent rheumatology practices, will work with the ACR and its committees on issues that confront members in small practices.

Introducing Daniel F. Battafarano, DO, MACP, MACR, Chair of the ACR’s New Workforce Solutions Steering Committee

Mary Beth Nierengarten  |  January 5, 2023

The new standing committee, devoted to addressing long-term workforce solutions in rheumatology, will be chaired by Daniel F. Battafarano, DO, MACP, MACR. Dr. Battafarano brings more than 35 years of leadership and experience in graduate medical education in rheumatology and internal medicine to the position.

Public Health Emergency Extended

From the College  |  January 5, 2023

Later this month, the Department of Health & Human Services (HHS) is expected to extend the public health emergency (PHE) for another 90 days. The PHE extension will allow for the continuation of many flexibilities instituted in 2020, including the expansion of such telehealth provisions as audio-only telehealth.

  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences